Yinlin Jack Chen - Aug 10, 2023 Form 3 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: SVP, Finance
Signature: /s/Lillian Smith, Attorney-in-Fact
Stock symbol: ALLO
Transactions as of: Aug 10, 2023
Transactions value $: $0
Form type: 3
Date filed: 8/14/2023, 07:28 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ALLO	Common Stock						77.5K	Aug 10, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ALLO	Stock Option (Right to Buy)							Aug 10, 2023	Common Stock	110K	$4.77	Direct	F2
holding	ALLO	Stock Option (Right to Buy)							Aug 10, 2023	Common Stock	24.4K	$5.04	Direct	F3
holding	ALLO	Stock Option (Right to Buy)							Aug 10, 2023	Common Stock	4.93K	$9.69	Direct	F4
holding	ALLO	Stock Option (Right to Buy)							Aug 10, 2023	Common Stock	55.8K	$13.31	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 70,402 shares of restricted stock units.
F2	Shares are 100% vested and exercisable
F3	25% of the shares subject to the stock option shall vest on March 22, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F4	25% of the shares subject to the stock option shall vest on March 23, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F5	1/3rd of the shares subject to the option vest on each anniversary measured from July 19th, 2022, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary.